By Karen Roman March Biosciences said it appointed Gurpreet Ratra, Ph.D., as Chief Business Officer. Dr. Ratra has more than 25 years of experience in the life science industry including cell and gene therapy, as well as equity research leadership, the...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it is presenting new research at the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held on December 1-4, 2025, in San Diego, California. Acumen and JCR Pharmaceuticals are...

By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapies and creating value, positions ReAlta for disciplined growth...

By Daniella Parra Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis. Sequana is working to relieve patients...

By Karen Roman Imviva Biotech said it will present its progress in allogenic cell therapy candidates in two oral presentations and five poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting, to be held on December 6-9,...

By Daniella Parra March Biosciences said that the FDA granted regenerative medicine advanced therapy its first-in-class CD5-targeted CAR-T cell therapy for relapsed or refractory CD5-positive T-cell lymphoma. The designation is based on encouraging early Phase 2 data showing clinical activity and...

By Daniella Parra Radiant Biotherapeutics presented data from their advancing a breakthrough antibody approach, the Multabody which uniquely harnesses natural mechanisms to effectively engage multiple disease targets with unmatched strength, precise tunability, and exceptional breadth, they said. They said RBT-101 achieved...

By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it appointed Adam S. Elinoff as Chief Financial Officer starting on Nov. 17, who joins from having previously served Amgen as its vice president of finance and treasurer. Mr. Elinoff has...

By Karen Roman Biopharmaceutical company Medera Inc. said the first patient has been dosed in Phase 2 of its MUSIC-HFrEF clinical trial using gene therapy for heart failure with reduced ejection fraction. The advancement comes after a positive recommendation and...

By Karen Roman Oncology-focused biotech company SkylineDx said results from its MERLIN_001 trial, the largest evaluation of a genomic test in cutaneous melanoma, were published in the October 2025 issue of JAMA Surgery. The study shows the test classified T1-T3...